Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Decreased pulse rate01:14

Decreased pulse rate

Bradycardia is a medical condition in which the heart rate is slower than normal. It occurs when the heart's natural pacemaker, the sinus node, generates slower electrical impulses than the standard rhythm. In adults, bradycardia is diagnosed when the pulse rate falls below 60 beats per minute, indicating a deviation from the normal heart rate range.
There are specific risk factors that can elevate the likelihood of developing bradycardia. Advanced age is a significant factor, with bradycardia...
Imbalances in Cardiac Output01:26

Imbalances in Cardiac Output

The heart's primary function is to pump blood throughout the body, maintaining a balance between blood sent out (cardiac output) and blood returning (venous return). If this balance is disrupted, it can result in congestive heart failure (CHF), a severe condition where the heart becomes an inefficient pump, leading to inadequate blood circulation.
CHF can occur due to the failure of either side of the heart. Left-side failure leads to pulmonary congestion—the right side continues to send blood...
Blood Studies for Cardiovascular System I: Cardiac Biomarkers01:20

Blood Studies for Cardiovascular System I: Cardiac Biomarkers

Cardiac biomarkers are enzymes, proteins, and hormones released into the blood when cardiac cells are injured. They are powerful tools for triaging.
The essential diagnostic tools for detecting myocardial necrosis and monitoring individuals suspected of having acute coronary syndrome (ACS) include:
Troponins
Troponins, particularly cardiac troponins I and T, are the most precise and sensitive markers of myocardial injury. They are detectable within 4-6 hours of myocardial injury and remain...
Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

Aging of the venous valves as a new risk factor for venous thrombosis in the elderly: the BATAVIA study.

Journal of thrombosis and haemostasis : JTH·2017
Same author

Linking.

Journal of thrombosis and haemostasis : JTH·2016
Same author

Bakers' cyst and tibiofemoral abnormalities are more distinctive MRI features of symptomatic osteoarthritis than patellofemoral abnormalities.

RMD open·2016
Same author

Two decades of haemophilia treatment in the Netherlands, 1972-92.

Haemophilia : the official journal of the World Federation of Hemophilia·2016
Same author

Emotional adjustment of children and adolescents with haemophilia in relation to the HIV threat.

Haemophilia : the official journal of the World Federation of Hemophilia·2016
Same author

Risk of venous thrombosis in persons with increased body mass index and interactions with other genetic and acquired risk factors.

Journal of thrombosis and haemostasis : JTH·2016

相关实验视频

Updated: Jul 9, 2026

Implantation of the Syncardia Total Artificial Heart
16:11

Implantation of the Syncardia Total Artificial Heart

Published on: July 18, 2014

血友病携带者中缺血性心脏病的死亡率降低

A Srámek1, M Kriek, F R Rosendaal

  • 1Department of Clinical Epidemiology, Leiden University Medical Center, Netherlands.

Lancet (London, England)
|August 9, 2003
PubMed
概括

血友病携带者血凝能力轻微下降,显著降低了因缺血性心脏病死亡的风险. 这一发现强调了低凝血性对心血管疾病死亡率的保护作用.

科学领域:

  • 心血管科学 心血管科学
  • 血液学 血液学 血液学
  • 流行病学 流行病学

背景情况:

  • 凝血是缺血性心血管疾病的一个关键因素.
  • 研究表明,极端的低凝血性提供了对缺血性心血管疾病的保护.
  • 这项研究调查了血友病携带者的死亡率,他们经常表现出轻微的低凝血能力,没有临床症状.

研究的目的:

  • 调查血友病携带者的整体死亡率和心血管死亡率.
  • 为了确定轻微的低凝血是否会影响死亡风险.
  • 为了将血友病携带者的死亡率与普通人口进行比较.

主要方法:

  • 在荷兰,对1012名患有血友病的母亲进行了从出生到死亡的跟踪.
  • 生命状态和死亡原因记录在41,984个人年内.
  • 死亡率与荷兰一般女性人口的死亡率进行了比较,使用标准化死亡率 (SMR),根据年龄和日历时期进行调整.

主要成果:

  • 总体死亡率降低了22% (SMR 0.78). 这是一个很好的结果.
  • 缺血性心脏病导致的死亡人数明显减少了36% (SMR 0.64).
  • 脑中风的死亡率没有显著下降 (SMR 0.76),并注意到脑外出血导致死亡的风险增加 (SMR 27.78),尽管死亡人数较少.

更多相关视频

Pre-clinical Model of Cardiac Donation after Circulatory Death
06:26

Pre-clinical Model of Cardiac Donation after Circulatory Death

Published on: August 2, 2019

A High-Fidelity Porcine Model of Orthotopic Heart Transplantation Following Donation after Circulatory Death
07:08

A High-Fidelity Porcine Model of Orthotopic Heart Transplantation Following Donation after Circulatory Death

Published on: June 6, 2025

相关实验视频

Last Updated: Jul 9, 2026

Implantation of the Syncardia Total Artificial Heart
16:11

Implantation of the Syncardia Total Artificial Heart

Published on: July 18, 2014

Pre-clinical Model of Cardiac Donation after Circulatory Death
06:26

Pre-clinical Model of Cardiac Donation after Circulatory Death

Published on: August 2, 2019

A High-Fidelity Porcine Model of Orthotopic Heart Transplantation Following Donation after Circulatory Death
07:08

A High-Fidelity Porcine Model of Orthotopic Heart Transplantation Following Donation after Circulatory Death

Published on: June 6, 2025

结论:

  • 轻微降低血液凝结能力显示出对致命缺血性心脏病的保护作用.
  • 这些发现表明,针对凝血的潜在治疗或预防策略.
  • 进一步的研究可能会探索这种保护作用背后的机制.